{"gene":"MAPK3","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1991,"finding":"Bacterially expressed mouse Erk-1 is an active serine/threonine kinase that also autophosphorylates on tyrosine; treatment with serine/threonine phosphatase 2A or tyrosine phosphatase 1B significantly decreased its kinase activity, and Erk-1 could reactivate ribosomal protein S6 kinase (S6KII) in vitro.","method":"Bacterial expression, in vitro kinase assay, phosphatase treatment, substrate reactivation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with enzymatic assays and phosphatase treatment in a single focused study","pmids":["1717989"],"is_preprint":false},{"year":1992,"finding":"p44mapk (ERK1) is activated in a biphasic manner by growth factors (alpha-thrombin, PDGF, serum); activation requires dual phosphorylation on tyrosine and threonine, and the late/sustained phase of activation correlates strictly with mitogenic potential and DNA synthesis.","method":"Epitope-tagged expression in fibroblasts, in vitro kinase assay (myelin basic protein phosphorylation), phosphoamino acid analysis","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstituted functional kinase assay replicated across multiple growth factor stimuli, independently corroborated by other papers in the corpus","pmids":["1372523","1603090"],"is_preprint":false},{"year":1993,"finding":"Activation of p42mapk/p44mapk is required for growth factor-stimulated fibroblast proliferation and gene transcription; antisense reduction of p42/p44mapk expression (by ~90%) or overexpression of kinase-deficient mutants (T192A or Y194F) inhibited MAP kinase activation, collagenase promoter-driven transcription, and cell growth in proportion to the extent of MAP kinase inhibition.","method":"Antisense RNA expression, dominant-negative kinase mutant overexpression, reporter gene assay (CAT), cell growth assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent loss-of-function approaches (antisense and dominant-negative), replicated phenotypes, multiple orthogonal readouts","pmids":["8397401"],"is_preprint":false},{"year":1993,"finding":"Upon mitogenic stimulation, p42mapk and p44mapk translocate from the cytoplasm into the nucleus rapidly (within 15 min) and persistently (throughout G1); this translocation is reversible, coupled to mitogenic potential, and does not occur with non-mitogenic stimuli. In contrast, the upstream activator p45mapkk remains cytoplasmic even during prolonged stimulation.","method":"Immunofluorescence with specific antibodies, transfection of epitope-tagged recombinant MAP kinases, subcellular fractionation, live cell imaging","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization with multiple methods (antibodies + tagged constructs), functional correlation to mitogenic stimulus established, independently reproduced across labs","pmids":["8394845"],"is_preprint":false},{"year":1993,"finding":"Human p44erk1 (ERK1) expressed as a GST fusion in E. coli autophosphorylates at the regulatory Tyr-204 (and additional sites); activity is strongly reduced by tyrosine phosphatase CD45 but not by serine/threonine phosphatase 2A; p56lck phosphorylates ERK1 at two autophosphorylation sites including Tyr-204; MAP kinase kinase (MEK) further activates ERK1 primarily through enhanced tyrosine phosphorylation.","method":"Bacterial expression (GST fusion), in vitro kinase assay (myelin basic protein substrate), phosphatase treatment, site-directed mutagenesis (K71A), MEK activation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in vitro with mutagenesis and multiple phosphatase/kinase experiments in a single rigorous study","pmids":["7687743"],"is_preprint":false},{"year":1993,"finding":"The sustained (late) phase of p44mapk activation, but not the transient early phase, is specifically required for mitogenic signaling; pertussis toxin abolished the late phase and mitogenicity; non-mitogenic stimuli (thrombin-receptor peptide) induced only the early phase. Co-stimulation of FGF with TMP (a non-mitogenic agonist) synergistically potentiated late-phase p44mapk activation and DNA synthesis.","method":"In vitro kinase assay, pharmacological inhibition (pertussis toxin, hirudin), DNA synthesis assay (3H-thymidine incorporation)","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pharmacological perturbations and kinetics correlated with mitogenic readout, corroborated by other studies in the corpus","pmids":["8380983"],"is_preprint":false},{"year":1995,"finding":"Ligation of beta1 integrins (by fibronectin adhesion or antibody cross-linking) rapidly activates p44erk-1 and p42erk-2 through tyrosine phosphorylation; disruption of actin filaments with cytochalasin D completely abolishes this integrin-mediated MAP kinase activation, indicating actin cytoskeleton integrity is required.","method":"Cell adhesion assay, anti-integrin antibody cross-linking, immunoprecipitation kinase assay, cytochalasin D treatment, phosphotyrosine Western blot","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional readouts with pharmacological perturbation, single lab, two orthogonal approaches","pmids":["7814385"],"is_preprint":false},{"year":1995,"finding":"Sustained p42/p44MAPK (ERK1/2) activation during G1 phase is required to pass the restriction point; p44mapk and p42mapk activities are elevated throughout G1 and decline to negligible values at the G1/S transition, whereas CDK2 activity continues to rise through S phase.","method":"Cell cycle synchronization, immunoprecipitation kinase assay (MBP substrate), phosphoamino acid analysis, CDK2 activity assay","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — quantitative kinase assays across defined cell cycle stages with multiple synchronization methods, independently replicated across the corpus","pmids":["7775600"],"is_preprint":false},{"year":1996,"finding":"Persistent activation of p42/p44MAPK positively regulates cyclin D1 expression: dominant-negative MKK1, kinase-dead p44MAPK, or MKP-1 overexpression strongly inhibited cyclin D1 promoter activity and protein; constitutively active MKK1 increased cyclin D1 in a growth factor-independent manner; activation of the Raf→MKK1→p42/p44MAPK cascade alone (via DeltaRaf-1:ER chimera) was sufficient to fully induce cyclin D1.","method":"Co-transfection of dominant-negative and constitutively active constructs, reporter gene assay (cyclin D1 promoter-luciferase/CAT), Western blot, inducible Raf-ER chimera","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple gain- and loss-of-function approaches with direct promoter readout and protein-level confirmation, independently corroborated","pmids":["8702807"],"is_preprint":false},{"year":1997,"finding":"The p42/p44MAPK cascade induces expression of the dual-specificity phosphatases MKP-1 and MKP-2, forming a negative feedback loop; constitutively active MKK-1 or v-ras caused constitutive MKP-1/MKP-2 expression, and the MEK inhibitor PD098059 blocked both MAP kinase activation and MKP induction.","method":"Western blot with specific antibodies, dominant active/oncogenic constructs, pharmacological inhibition (PD098059), inducible DeltaRaf-1:ER chimera","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple gain-of-function models and pharmacological inhibition converge on the same conclusion, independently replicated","pmids":["8995446"],"is_preprint":false},{"year":1999,"finding":"p42MAPK and p44MAPK directly phosphorylate MKP-1 on two C-terminal serine residues (Ser359 and Ser364) both in vivo and in vitro; this phosphorylation does not alter MKP-1's intrinsic phosphatase activity toward p44MAPK but stabilizes MKP-1 protein by attenuating ubiquitin-proteasome-mediated degradation.","method":"In vitro kinase assay, site-directed mutagenesis (Ser359/Ser364), ubiquitin-proteasome inhibitor experiments, pulse-chase protein stability assay, in vivo phosphorylation","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis plus in vivo confirmation, published in Science, multiple orthogonal methods in one study","pmids":["10617468"],"is_preprint":false},{"year":2003,"finding":"ERK1/2 directly phosphorylates sphingosine kinase 1 (SphK1) at Ser225, activating its enzyme activity and inducing translocation from the cytosol to the plasma membrane; mutation of Ser225 abolishes agonist-mediated SphK1 activation and membrane translocation.","method":"In vitro kinase assay, site-directed mutagenesis (Ser225), subcellular fractionation, enzyme activity assay, multiple lines of evidence for ERK1/2 as the kinase","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro phosphorylation, mutagenesis, and membrane localization assay with multiple orthogonal methods in one study","pmids":["14532121"],"is_preprint":false},{"year":2005,"finding":"ERK1 and ERK2 are both required for T cell positive selection in vivo; ERK1/2 activity is selectively retained during beta-selection-driven proliferation but is not required for completion of differentiation to the CD4+CD8+ preselection stage; ERK1/2 differentially affects CD4 vs. CD8 T cell maturation.","method":"Targeted gene deletion (Erk1 and Erk2 knockout mice), flow cytometry, thymocyte developmental analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic loss-of-function with defined cellular phenotypes, single and double knockout analysis","pmids":["16226508"],"is_preprint":false},{"year":2009,"finding":"ERK1/2 in granulosa cells are essential in vivo for LH-induced oocyte resumption of meiosis, ovulation, and luteinization; C/EBPbeta is a critical downstream transcriptional mediator of ERK1/2 activation in this pathway, as demonstrated by granulosa cell-specific disruption of Cebpb.","method":"Conditional knockout of Erk1 and Erk2 in mouse granulosa cells, genetic epistasis (Cebpb knockout), biochemical analyses, in vivo ovulation assay","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockouts in vivo with pathway epistasis, published in Science, multiple orthogonal readouts","pmids":["19443782"],"is_preprint":false},{"year":2009,"finding":"Total ERK1/2 activity level (not isoform identity) is the key determinant for cell proliferation; combined single and double ERK1/ERK2 silencing showed that the apparent dominant role of ERK2 was due to its higher expression level, not isoform-specific function; ERK1 contribution is revealed when ERK2 activation is experimentally clamped.","method":"siRNA silencing of ERK1 and/or ERK2, cell proliferation assay, expression level analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with quantitative proliferation readout, single lab, single primary method","pmids":["19242111"],"is_preprint":false},{"year":2010,"finding":"ERK1/2 and Akt1 (but not Akt2) crosstalk regulates arterial morphogenesis; suppression of PI3K/Akt1 activity restores ERK1/2 activation and rescues arterial development defects in synectin-deficient mice and zebrafish; constitutively active ERK1/2 constructs in endothelial cells are sufficient to restore impaired arteriogenesis.","method":"Genetic knockouts (synectin-deficient mice), Akt1/Akt2-specific knockdowns, constitutively active ERK1/2 construct, in vivo and in vitro arterial morphogenesis assays, zebrafish knockdown","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (mouse and zebrafish), rescue experiments with constitutively active construct, multiple orthogonal approaches","pmids":["20237411"],"is_preprint":false},{"year":2015,"finding":"ERK1 and ERK2 are functionally redundant during mouse development; total ERK1/2 activity level determines developmental outcome (placenta and embryo viability); transgenic expression of ERK1 fully rescues the embryonic and placental lethal phenotype caused by loss of ERK2.","method":"Genetic complementation in mice (multiple Erk1/Erk2 allele combinations), transgenic ERK1 rescue, developmental outcome scoring","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo allelic series and full genetic rescue establish functional redundancy conclusively","pmids":["26235619"],"is_preprint":false},{"year":2015,"finding":"ERK1 and ERK2 regulate chondrocyte terminal differentiation; conditional knockout of ERK1/2 in hypertrophic chondrocytes (Osx-Cre) caused expanded hypertrophic zones, decreased Mmp13 and Osteopontin, and downregulation of Egr1/Egr2 transcription factors; MEK1-ERK signaling activates the Osteopontin promoter in part through Egr1 and Egr2.","method":"Conditional knockout (Osx-Cre), histology, in situ hybridization, qRT-PCR, transient transfection reporter assays","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional knockout with defined molecular mechanism and reporter assay validation","pmids":["25401279"],"is_preprint":false},{"year":2015,"finding":"ERK1 regulates hematopoietic stem cell niches by controlling osteoclastogenesis through M-CSF receptor (M-CSFR) expression on myeloid progenitors; ERK1-deficient mice show mild osteopetrosis, impaired HSC lodging and homing, reduced GMP frequency, and decreased M-CSFR expression on hematopoietic progenitors upstream of osteoclasts.","method":"ERK1 knockout mice, serial bone marrow transplantation, flow cytometry, in vitro and in vivo osteoclastogenesis assay, Western blot (M-CSFR expression)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic knockout with defined cellular phenotype and molecular mechanism, single lab","pmids":["22303456"],"is_preprint":false},{"year":2017,"finding":"ERK1/2 phosphorylates INTS11, the catalytic subunit of the Integrator complex, following EGF stimulation; activated ERK1/2 is recruited to immediate early genes at their promoters; Integrator is required to transduce ERK1/2 transcriptional responses at immediate early genes and their enhancers.","method":"Pharmacological ERK inhibition, ChIP-seq, Integrator subunit depletion, phosphorylation assays, cancer cell growth assays","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and phosphorylation data with depletion experiments, single lab","pmids":["28982763"],"is_preprint":false},{"year":2017,"finding":"HDAC6 deacetylates ERK1 at Lys-72 to stimulate its activity; CBP and p300 acetyltransferases acetylate ERK1; acetylation-mimicking mutation K72Q reduces ERK1 phosphorylation and enzymatic activity in vitro toward ELK1; ERK1 and HDAC6 form a positive feed-forward loop (ERK1 phosphorylates HDAC6 to increase its deacetylase activity, and HDAC6 deacetylates ERK1 to increase its kinase activity).","method":"Co-IP, HDAC6 knockdown, HDAC inhibitor treatment, site-directed mutagenesis (K72Q, K72R), in vitro kinase assay (ELK1 substrate), mass spectrometry (acetylation site identification), luciferase reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, mass spectrometry identification of acetylation site, multiple orthogonal methods in one study","pmids":["29259132"],"is_preprint":false},{"year":2015,"finding":"SUV420H1 trimethylates ERK1 at Lys-302 and Lys-361; substitution of these methylation sites diminishes ERK1 phosphorylation; SUV420H1 knockdown reduces phospho-ERK1, total ERK1 protein, and ERK1 transcript levels.","method":"In vitro methylation assay, site-directed mutagenesis (K302/K361), SUV420H1 knockdown, Western blot, qRT-PCR","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro methylation assay with mutagenesis and knockdown, single lab","pmids":["26586479"],"is_preprint":false},{"year":2015,"finding":"ERK1/2 can feedback-regulate MEK1/2 levels: ERK1/2 activity upregulates MEK1 at the transcriptional level and downregulates MEK2 at the post-translational level via the proteasome; ERK1/2 knockdown abrogates both regulations.","method":"ΔRaf-1:ER and B-Raf(V600E) inducible systems, ERK1/2 siRNA knockdown, qPCR, luciferase promoter and 3'UTR reporters, proteasome inhibitors (MG132, bortezomib), Western blot","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods and genetic rescue, single lab","pmids":["26163823"],"is_preprint":false},{"year":2015,"finding":"Transient pharmacological inhibition of MAPK3/1 (with PD0325901) abolishes LH/hCG-induced ovulation in mice; MAPK3/1 regulates ovulation at least in part through transcriptional induction of Egr1, which binds to and activates the Ptgs2 (COX-2) promoter in granulosa cells.","method":"In vivo pharmacological inhibition, ChIP assay (Egr1 binding to Ptgs2 promoter), Egr1 siRNA knockdown in primary granulosa cells, qRT-PCR, ovulation counting","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological inhibition plus ChIP epistasis and siRNA validation, multiple orthogonal methods","pmids":["25803847"],"is_preprint":false},{"year":2017,"finding":"MAPK3/1 participates in primordial follicle activation through mTORC1-KITL signaling in pre-granulosa cells; inhibition of MAPK3/1 with U0126 reduces follicle activation and decreases phosphorylation of Tsc2, S6K1, and rpS6 (mTORC1 targets) and KITL expression, and also decreases Akt phosphorylation and Foxo3 nuclear export in oocytes.","method":"Ex vivo ovary culture, pharmacological inhibition (U0126), Western blot, immunofluorescence","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition with pathway-level readouts, single lab, multiple downstream markers measured","pmids":["28218391"],"is_preprint":false},{"year":2019,"finding":"ERK1/2 loss in quiescent adult endothelium (endothelial Erk2 knockout on Erk1-null background) causes hypertension, decreased eNOS expression, increased endothelin-1, widespread endothelial-to-mesenchymal transition (EndMT) via TGFβ signaling, fibrosis, and death; ERK1/2 signaling is required to suppress TGFβ pathway and maintain endothelial identity.","method":"Conditional knockout (endothelial-specific Erk2 deletion on Erk1-/- background), endothelial fate mapping, immunostaining, RNA-seq, HUVEC in vitro knockdown, computational causal modeling","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional knockout with in vitro mechanistic validation, fate mapping, transcriptomic causal analysis, and multiple endpoints","pmids":["31196980"],"is_preprint":false},{"year":2019,"finding":"Erk1/2 directly phosphorylate FGF receptor 1 (FGFR1) at a specific serine residue and multiple threonine residues in FRS2, substantially reducing tyrosine phosphorylation of FGFR1 and its downstream signaling; simultaneous inhibition of both Erk1/2 and p38 kinase leads to prolonged FGFR1/FRS2 tyrosine phosphorylation, revealing a crosstalk between p38 and Erk1/2 in negative feedback of FGF signaling.","method":"Pharmacological inhibition (ERK and p38 inhibitors), phospho-Western blot, anisomycin p38 activation, stable cell lines (FGFR1-expressing NIH3T3 and U2OS)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with phospho-readouts at multiple nodes, single lab, two orthogonal cell systems","pmids":["31013829"],"is_preprint":false},{"year":2017,"finding":"S-nitrosylation of ERK1 at Cys183 inhibits ERK1/2 phosphorylation and promotes glioma cell apoptosis; C183A mutation (preventing S-nitrosylation) partially reverses NO donor-induced reductions in cell viability and ERK1/2 phosphorylation; inverse correlation between S-nitrosylation and phosphorylation was confirmed in human glioma tissues.","method":"Biotin switch assay, site-directed mutagenesis (C183A), Western blot, flow cytometry (apoptosis), cell viability assay, NO donor treatment","journal":"International journal of molecular medicines","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus biotin switch and cellular functional assay, single lab","pmids":["29286066"],"is_preprint":false},{"year":1998,"finding":"Region-specific subcellular localization of activated p42/p44MAPK determines their functional targets in vivo: in hippocampal neurons after ECS, activated MAPKs are cytoplasmic and phosphorylate cytoplasmic substrate MAP2c but not nuclear c-Fos; in cortical neurons, activated MAPKs localize to both nucleus and cytoplasm and phosphorylate both MAP2c and c-Fos.","method":"In vivo electroconvulsive shock, immunohistochemistry (phospho-MAPK), pharmacological inhibition (PD098059), immunoblot for MAP2c phosphorylation, c-Fos immunohistochemistry","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo localization linked to substrate phosphorylation via pharmacological inhibition, single lab","pmids":["9453550"],"is_preprint":false},{"year":2009,"finding":"ERK-1 kinase activity prevents TNF+cycloheximide-induced apoptosis through phosphorylation of Bad and inhibition of Bax translocation to mitochondria, thereby preventing cytochrome c release; a kinase-dead ERK-1 (K71R) sensitizes cells to apoptosis; these effects are mediated through the intrinsic mitochondrial pathway.","method":"ERK-1 and K71R kinase-dead overexpression in HeLa cells, Western blot (Bad phosphorylation, Bax, Bcl-2, cytochrome c), cell death assay, caspase inhibitor experiments","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and kinase-dead constructs with mechanistic downstream readouts, single lab","pmids":["19777442"],"is_preprint":false}],"current_model":"MAPK3 (ERK1) is a proline-directed serine/threonine kinase activated by MEK1/2-mediated dual phosphorylation at Thr202 and Tyr204; it translocates from the cytoplasm to the nucleus upon mitogenic stimulation (coupled to its sustained activation), where it phosphorylates transcription factors (Elk1, c-Fos, Egr1) and cytoplasmic substrates (MAP2c, FRS2, FGFR1, Bad, SphK1 Ser225), and is regulated post-translationally by acetylation (CBP/p300, reversed by HDAC6 at Lys-72), methylation (SUV420H1 at Lys-302/361), and S-nitrosylation (at Cys183); it operates redundantly with ERK2 in most developmental and proliferative contexts (total ERK activity being the key determinant), while exhibiting isoform-specific roles in macrophage/osteoclast biology and arteriogenesis; and it participates in multiple negative feedback loops by phosphorylating and stabilizing MKP-1/MKP-2 phosphatases and by transcriptionally and post-translationally regulating MEK1/2 levels."},"narrative":{"mechanistic_narrative":"MAPK3 (ERK1) is a dual-specificity-regulated proline-directed serine/threonine kinase that serves as a terminal effector of the Raf→MEK→ERK mitogenic cascade, converting growth factor and integrin signals into proliferative and developmental gene-expression programs [PMID:1717989, PMID:1372523, PMID:1603090, PMID:7814385, PMID:8702807]. Its catalytic activation requires dual phosphorylation on tyrosine and threonine by MAP kinase kinase (MEK), and it can autophosphorylate on tyrosine; activity is reversed by serine/threonine and tyrosine phosphatases [PMID:1717989, PMID:7687743]. A defining feature is that the sustained, late phase of activation—not the transient early phase—is coupled to nuclear translocation throughout G1 and is specifically required for passage through the restriction point, induction of cyclin D1, and DNA synthesis [PMID:8394845, PMID:8380983, PMID:7775600, PMID:8702807]. In the nucleus and cytoplasm ERK1 phosphorylates a defined set of substrates including the transcriptional machinery via ELK1 and immediate-early gene programs (Egr1, c-Fos, the Integrator subunit INTS11), the cytoskeletal protein MAP2c, the pro-apoptotic regulator Bad, sphingosine kinase 1 (Ser225), and components of receptor feedback (FGFR1/FRS2) [PMID:14532121, PMID:25401279, PMID:28982763, PMID:29259132, PMID:9453550, PMID:19777442]. ERK1 embeds itself in multiple negative-feedback loops—directly phosphorylating and stabilizing the dual-specificity phosphatases MKP-1/MKP-2, attenuating FGFR1/FRS2 signaling, and transcriptionally and post-translationally tuning MEK1/2 levels [PMID:8995446, PMID:10617468, PMID:26163823, PMID:31013829]. Its kinase output is further set by reversible post-translational modification: acetylation by CBP/p300 reversed by HDAC6 deacetylation at Lys-72, SUV420H1-mediated methylation at Lys-302/361, and inhibitory S-nitrosylation at Cys183 [PMID:29259132, PMID:26586479, PMID:29286066]. In vivo, ERK1 functions largely redundantly with ERK2, with total ERK activity rather than isoform identity being the determinant of proliferation and development, while ERK1-selective roles emerge in osteoclast/HSC-niche and arteriogenic contexts [PMID:19242111, PMID:26235619, PMID:22303456]; genetic studies establish requirements in T-cell positive selection, ovarian follicle activation, ovulation and luteinization, chondrocyte terminal differentiation, and maintenance of endothelial identity against TGFβ-driven EndMT [PMID:16226508, PMID:19443782, PMID:20237411, PMID:25401279, PMID:25803847, PMID:28218391, PMID:31196980].","teleology":[{"year":1991,"claim":"Established ERK1 as a bona fide serine/threonine kinase whose activity depends on phosphorylation state and which can relay signal to downstream kinases, defining it as an enzyme in a cascade.","evidence":"Bacterial expression of mouse Erk-1 with in vitro kinase, phosphatase treatment, and S6KII reactivation assays","pmids":["1717989"],"confidence":"High","gaps":["Physiological upstream activator not yet identified","In vitro autophosphorylation may not reflect cellular activation mechanism"]},{"year":1992,"claim":"Showed that ERK1 activation by growth factors is biphasic and that the sustained late phase, not transient activation, correlates with mitogenic outcome—linking activation kinetics to cell fate.","evidence":"Epitope-tagged ERK1 in fibroblasts, in vitro MBP kinase assays, phosphoamino acid analysis across multiple growth factors","pmids":["1372523","1603090"],"confidence":"High","gaps":["Molecular basis for sustained vs transient kinetics unresolved","Nuclear vs cytoplasmic activity not yet separated"]},{"year":1993,"claim":"Demonstrated ERK1/2 are causally required for growth-factor-driven proliferation and gene transcription, moving beyond correlation to functional necessity.","evidence":"Antisense knockdown and dominant-negative (T192A/Y194F) mutants with reporter and growth assays in fibroblasts","pmids":["8397401"],"confidence":"High","gaps":["Direct transcriptional targets not defined here","ERK1 vs ERK2 contributions not separated"]},{"year":1993,"claim":"Defined the regulated nuclear translocation of ERK1/2 as mitogen-specific and persistent through G1, while the upstream activator stays cytoplasmic—establishing spatial control of signaling output.","evidence":"Immunofluorescence, tagged-construct transfection, and subcellular fractionation in stimulated cells","pmids":["8394845"],"confidence":"High","gaps":["Translocation machinery/NLS-like determinants not identified","Nuclear substrates not yet enumerated"]},{"year":1993,"claim":"Resolved the activation mechanism biochemically—autophosphorylation at Tyr-204, differential phosphatase sensitivity, and MEK acting mainly via tyrosine phosphorylation.","evidence":"GST-ERK1 in vitro kinase assays, CD45/PP2A treatment, K71A mutagenesis, and MEK activation","pmids":["7687743"],"confidence":"High","gaps":["Relative in vivo contribution of autophosphorylation vs MEK unclear","p56lck phosphorylation physiological relevance untested"]},{"year":1995,"claim":"Connected ERK1 activation to upstream adhesion and cytoskeletal context, showing integrin ligation activates ERK1 in an actin-dependent manner.","evidence":"Integrin cross-linking/fibronectin adhesion with IP kinase assays and cytochalasin D disruption","pmids":["7814385"],"confidence":"Medium","gaps":["Mechanism linking actin to ERK activation undefined","Single-lab pharmacological perturbation"]},{"year":1995,"claim":"Tied sustained ERK1/2 activity to the cell-cycle restriction point, defining its temporal window of action during G1.","evidence":"Cell-cycle synchronization with IP kinase and CDK2 assays","pmids":["7775600"],"confidence":"High","gaps":["Direct G1 effector substrates not identified in this study"]},{"year":1996,"claim":"Identified cyclin D1 as a key transcriptional output coupling sustained ERK activity to G1 progression, providing a mechanistic effector for the restriction-point requirement.","evidence":"Dominant-negative/constitutively active MKK1 and kinase-dead ERK, MKP-1, and Raf-ER chimera with cyclin D1 promoter reporters","pmids":["8702807"],"confidence":"High","gaps":["Direct transcription factors at the cyclin D1 promoter not pinpointed here"]},{"year":1997,"claim":"Revealed that the ERK cascade induces its own negative regulators (MKP-1/MKP-2), establishing transcriptional feedback control of pathway duration.","evidence":"Constitutively active MKK1/v-ras, PD098059 inhibition, and Raf-ER chimera with phosphatase immunoblots","pmids":["8995446"],"confidence":"High","gaps":["Transcription factors mediating MKP induction not defined"]},{"year":1999,"claim":"Showed ERK1/2 directly phosphorylates and stabilizes MKP-1, adding a post-translational layer to feedback that shapes signal duration without altering phosphatase activity.","evidence":"In vitro kinase assay, Ser359/Ser364 mutagenesis, pulse-chase stability, and proteasome inhibition","pmids":["10617468"],"confidence":"High","gaps":["The ubiquitin ligase targeting MKP-1 not identified"]},{"year":1998,"claim":"Demonstrated that the subcellular location of activated ERK in vivo dictates which substrate class (cytoplasmic MAP2c vs nuclear c-Fos) is phosphorylated, linking localization to functional specificity in neurons.","evidence":"In vivo electroconvulsive shock with phospho-MAPK immunohistochemistry and PD098059 inhibition across neuron types","pmids":["9453550"],"confidence":"Medium","gaps":["Determinants of region-specific localization unknown","Single-lab correlative localization"]},{"year":2003,"claim":"Added SphK1 as a direct ERK1/2 substrate, coupling ERK activity to sphingolipid signaling and membrane translocation of an effector enzyme.","evidence":"In vitro kinase assay, Ser225 mutagenesis, subcellular fractionation, and enzyme activity assays","pmids":["14532121"],"confidence":"High","gaps":["Physiological contexts of SphK1 activation by ERK1 not delineated"]},{"year":2005,"claim":"Established an in vivo developmental requirement for ERK1/2 in T-cell positive selection, distinguishing proliferation-linked from differentiation-linked activity.","evidence":"Erk1 and Erk2 knockout mice with flow cytometric thymocyte analysis","pmids":["16226508"],"confidence":"High","gaps":["Substrate basis for selection vs differentiation distinction unresolved"]},{"year":2009,"claim":"Defined an ovarian ERK1/2 program where C/EBPβ is the critical transcriptional mediator for LH-induced ovulation and luteinization, mapping a tissue-specific effector.","evidence":"Granulosa-cell conditional Erk1/Erk2 and Cebpb knockouts with in vivo ovulation assays","pmids":["19443782"],"confidence":"High","gaps":["Direct ERK1/2 substrates upstream of C/EBPβ not identified"]},{"year":2009,"claim":"Showed ERK1 kinase activity is anti-apoptotic via Bad phosphorylation and suppression of Bax/cytochrome c release, placing ERK1 on the intrinsic mitochondrial survival axis.","evidence":"ERK1 and kinase-dead K71R overexpression in HeLa with Bad/Bax/cytochrome c immunoblots and death assays","pmids":["19777442"],"confidence":"Medium","gaps":["Direct vs indirect Bad phosphorylation by ERK1 not fully resolved","Single-lab overexpression system"]},{"year":2009,"claim":"Tested whether ERK1 vs ERK2 functional differences reflect isoform identity, concluding total ERK activity (driven by expression level) governs proliferation.","evidence":"Single and combined ERK1/ERK2 siRNA silencing with proliferation and expression analysis","pmids":["19242111"],"confidence":"Medium","gaps":["Single primary method (siRNA)","Contexts with genuine isoform-specific roles not excluded"]},{"year":2010,"claim":"Identified an ERK1/2–Akt1 crosstalk node controlling arterial morphogenesis, with constitutively active ERK1/2 sufficient to rescue arteriogenesis defects.","evidence":"Synectin-deficient mice/zebrafish, Akt isoform knockdowns, and constitutively active ERK1/2 rescue in endothelium","pmids":["20237411"],"confidence":"High","gaps":["Endothelial ERK substrates driving arteriogenesis unmapped"]},{"year":2015,"claim":"Established genetically that ERK1 and ERK2 are functionally redundant in development and that transgenic ERK1 rescues ERK2 loss—total activity, not isoform, sets developmental outcome.","evidence":"Mouse Erk1/Erk2 allelic series with transgenic ERK1 rescue and developmental scoring","pmids":["26235619"],"confidence":"High","gaps":["Tissue contexts with non-redundant roles not fully enumerated"]},{"year":2015,"claim":"Mapped a chondrocyte terminal-differentiation program in which ERK1/2 acts through Egr1/Egr2 to control Osteopontin and Mmp13 expression.","evidence":"Osx-Cre conditional Erk1/2 knockout with histology, in situ hybridization, and Osteopontin promoter reporters","pmids":["25401279"],"confidence":"High","gaps":["Direct ERK phosphorylation events upstream of Egr1/Egr2 not shown"]},{"year":2015,"claim":"Revealed an ERK1-selective role in regulating the HSC niche via M-CSFR-dependent osteoclastogenesis, indicating isoform-specific functions in myeloid/bone biology.","evidence":"ERK1 knockout mice, bone-marrow transplantation, flow cytometry, and osteoclastogenesis assays","pmids":["22303456"],"confidence":"Medium","gaps":["Mechanism linking ERK1 to M-CSFR expression undefined","Single-lab study"]},{"year":2015,"claim":"Added a methylation layer of ERK1 regulation, showing SUV420H1 trimethylates Lys-302/361 to sustain ERK1 phosphorylation and expression.","evidence":"In vitro methylation, K302/K361 mutagenesis, and SUV420H1 knockdown with immunoblot/qRT-PCR","pmids":["26586479"],"confidence":"Medium","gaps":["Mechanism by which methylation affects phosphorylation/transcript unclear","Single-lab"]},{"year":2015,"claim":"Demonstrated ERK1/2 feedback regulation of upstream MEK by oppositely controlling MEK1 (transcriptionally up) and MEK2 (proteasomally down), refining cascade homeostasis.","evidence":"ΔRaf-1:ER/B-Raf(V600E) systems, ERK siRNA, promoter/3'UTR reporters, and proteasome inhibitors","pmids":["26163823"],"confidence":"Medium","gaps":["E3 ligase mediating MEK2 turnover not identified","Single-lab"]},{"year":2015,"claim":"Mapped the ovulation mechanism to ERK-driven Egr1 induction that activates the Ptgs2/COX-2 promoter, defining a direct transcriptional axis for fertility.","evidence":"In vivo PD0325901 inhibition, Egr1 ChIP at Ptgs2 promoter, and Egr1 siRNA in granulosa cells","pmids":["25803847"],"confidence":"High","gaps":["Direct ERK substrate upstream of Egr1 not pinpointed"]},{"year":2017,"claim":"Connected ERK1/2 to primordial follicle activation via mTORC1-KITL signaling in pre-granulosa cells, broadening the ovarian role to earlier follicle stages.","evidence":"Ex vivo ovary culture with U0126 and immunoblot/immunofluorescence of mTORC1/Akt/Foxo3 markers","pmids":["28218391"],"confidence":"Medium","gaps":["Direct ERK targets in the mTORC1-KITL axis unknown","Pharmacological inhibition only"]},{"year":2017,"claim":"Identified the Integrator catalytic subunit INTS11 as an ERK1/2 substrate and showed Integrator transduces ERK transcriptional responses at immediate-early genes and enhancers.","evidence":"ERK inhibition, ChIP-seq, Integrator depletion, and phosphorylation assays in cancer cells","pmids":["28982763"],"confidence":"Medium","gaps":["Direct INTS11 phosphosites and their consequences not fully defined","Single-lab"]},{"year":2017,"claim":"Added inhibitory S-nitrosylation at Cys183 as a regulatory modification that suppresses ERK phosphorylation and promotes glioma apoptosis, linking NO signaling to ERK output.","evidence":"Biotin switch assay, C183A mutagenesis, apoptosis/viability assays, and human glioma tissue correlation","pmids":["29286066"],"confidence":"Medium","gaps":["Mechanism by which Cys183 modification blocks activation loop phosphorylation unclear","Single-lab"]},{"year":2017,"claim":"Established acetylation/deacetylation control of ERK1 via CBP/p300 and HDAC6 at Lys-72, forming an ERK1–HDAC6 feed-forward loop that tunes kinase activity.","evidence":"Co-IP, HDAC6 knockdown, K72Q/K72R mutagenesis, in vitro ELK1 kinase assay, and mass spectrometry","pmids":["29259132"],"confidence":"High","gaps":["In vivo physiological role of Lys-72 acetylation not established"]},{"year":2019,"claim":"Showed ERK1/2 is required in quiescent endothelium to suppress TGFβ-driven EndMT and maintain endothelial identity, extending ERK function beyond proliferation to tissue homeostasis.","evidence":"Endothelial conditional Erk2 knockout on Erk1-null background with fate mapping, RNA-seq, and HUVEC knockdown","pmids":["31196980"],"confidence":"High","gaps":["Direct ERK substrates suppressing the TGFβ program not identified"]},{"year":2019,"claim":"Demonstrated ERK1/2 directly phosphorylates FGFR1 and FRS2 to dampen receptor tyrosine phosphorylation, defining a negative-feedback brake on FGF signaling with p38 crosstalk.","evidence":"Pharmacological ERK/p38 inhibition with phospho-Western blots in FGFR1-expressing cell lines","pmids":["31013829"],"confidence":"Medium","gaps":["Specific FRS2/FGFR1 phosphosites and their direct effects partially defined","Single-lab pharmacology"]},{"year":null,"claim":"How the multiple post-translational modifications (acetylation, methylation, S-nitrosylation) integrate with MEK-driven activation-loop phosphorylation to set ERK1 output in vivo, and what distinguishes ERK1-selective contexts from redundant ones at the substrate level, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM cross-regulation to physiological signaling","Substrate-level basis for ERK1-specific roles undefined","Determinants of localization-dependent substrate selection unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,4,10,11,19,20,26,29]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,4,10,11]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,17,19,23]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,28]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,19,28]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,8,9,22,26]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,13,16,17,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[17,19,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[27,29]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[13,23,24]}],"complexes":[],"partners":["MAP2K1","MKP-1/DUSP1","HDAC6","SUV420H1","INTS11","SPHK1","FGFR1","FRS2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P27361","full_name":"Mitogen-activated protein kinase 3","aliases":["ERT2","Extracellular signal-regulated kinase 1","ERK-1","Insulin-stimulated MAP2 kinase","MAP kinase isoform p44","p44-MAPK","Microtubule-associated protein 2 kinase","p44-ERK1"],"length_aa":379,"mass_kda":43.1,"function":"Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway (PubMed:34497368). MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DEPTOR, FRS2 or GRB10) (PubMed:35216969). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Phosphorylates GJA1 at 'Ser-279' and 'Ser-282' resulting in an increase in GJA1 ubiquitination and ultimately lysosomal degradation (By similarity)","subcellular_location":"Cytoplasm; Nucleus; Membrane, caveola; Cell junction, focal adhesion","url":"https://www.uniprot.org/uniprotkb/P27361/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAPK3","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000102882","cell_line_id":"CID001204","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"CSNK2A2","stoichiometry":10.0},{"gene":"CAPZB","stoichiometry":4.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001204","total_profiled":1310},"omim":[{"mim_id":"621174","title":"CHOLESIN; CHLSN","url":"https://www.omim.org/entry/621174"},{"mim_id":"621173","title":"G PROTEIN-COUPLED RECEPTOR 146; GPR146","url":"https://www.omim.org/entry/621173"},{"mim_id":"621120","title":"DELTA-LIKE NONCANONICAL NOTCH LIGAND 2; DLK2","url":"https://www.omim.org/entry/621120"},{"mim_id":"621093","title":"OOCYTE/ZYGOTE/EMBRYO MATURATION ARREST 22; OZEMA22","url":"https://www.omim.org/entry/621093"},{"mim_id":"621055","title":"POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 1-LIKE; PABPC1L","url":"https://www.omim.org/entry/621055"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MAPK3"},"hgnc":{"alias_symbol":["ERK1","p44mapk","p44erk1","ERK-1"],"prev_symbol":["PRKM3"]},"alphafold":{"accession":"P27361","domains":[{"cath_id":"3.30.200.20","chopping":"32-124_353-370","consensus_level":"high","plddt":94.0408,"start":32,"end":370},{"cath_id":"1.10.510.10","chopping":"126-325","consensus_level":"high","plddt":92.5673,"start":126,"end":325}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P27361","model_url":"https://alphafold.ebi.ac.uk/files/AF-P27361-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P27361-F1-predicted_aligned_error_v6.png","plddt_mean":88.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAPK3","jax_strain_url":"https://www.jax.org/strain/search?query=MAPK3"},"sequence":{"accession":"P27361","fasta_url":"https://rest.uniprot.org/uniprotkb/P27361.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P27361/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P27361"}},"corpus_meta":[{"pmid":"22569528","id":"PMC_22569528","title":"ERK1/2 MAP kinases: structure, function, and regulation.","date":"2012","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/22569528","citation_count":1275,"is_preprint":false},{"pmid":"8702807","id":"PMC_8702807","title":"Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702807","citation_count":1110,"is_preprint":false},{"pmid":"8397401","id":"PMC_8397401","title":"Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8397401","citation_count":965,"is_preprint":false},{"pmid":"8394845","id":"PMC_8394845","title":"Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8394845","citation_count":621,"is_preprint":false},{"pmid":"19443782","id":"PMC_19443782","title":"MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility.","date":"2009","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19443782","citation_count":522,"is_preprint":false},{"pmid":"14532121","id":"PMC_14532121","title":"Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14532121","citation_count":473,"is_preprint":false},{"pmid":"27342992","id":"PMC_27342992","title":"Negative feedback regulation of the ERK1/2 MAPK pathway.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27342992","citation_count":421,"is_preprint":false},{"pmid":"18846109","id":"PMC_18846109","title":"Tumour cell survival signalling by the ERK1/2 pathway.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18846109","citation_count":419,"is_preprint":false},{"pmid":"10617468","id":"PMC_10617468","title":"Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation.","date":"1999","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10617468","citation_count":360,"is_preprint":false},{"pmid":"16880823","id":"PMC_16880823","title":"MAPK signalling: ERK5 versus ERK1/2.","date":"2006","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/16880823","citation_count":333,"is_preprint":false},{"pmid":"8995446","id":"PMC_8995446","title":"The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8995446","citation_count":318,"is_preprint":false},{"pmid":"1603090","id":"PMC_1603090","title":"Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity.","date":"1992","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1603090","citation_count":295,"is_preprint":false},{"pmid":"7706248","id":"PMC_7706248","title":"Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7706248","citation_count":283,"is_preprint":false},{"pmid":"16226508","id":"PMC_16226508","title":"The role of erk1 and erk2 in multiple stages of T cell development.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16226508","citation_count":280,"is_preprint":false},{"pmid":"7814385","id":"PMC_7814385","title":"Matrix/integrin interaction activates the mitogen-activated protein kinase, p44erk-1 and p42erk-2.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7814385","citation_count":260,"is_preprint":false},{"pmid":"15153095","id":"PMC_15153095","title":"Oxidative neuronal injury. The dark side of ERK1/2.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15153095","citation_count":232,"is_preprint":false},{"pmid":"27376062","id":"PMC_27376062","title":"ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?","date":"2016","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27376062","citation_count":228,"is_preprint":false},{"pmid":"19843173","id":"PMC_19843173","title":"ERK and cell death: ERK1/2 in neuronal death.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19843173","citation_count":228,"is_preprint":false},{"pmid":"15107845","id":"PMC_15107845","title":"Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses.","date":"2004","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15107845","citation_count":186,"is_preprint":false},{"pmid":"8380983","id":"PMC_8380983","title":"Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist.","date":"1993","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8380983","citation_count":167,"is_preprint":false},{"pmid":"15814736","id":"PMC_15814736","title":"ERK1/2 regulates epidermal chemokine expression and skin inflammation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15814736","citation_count":164,"is_preprint":false},{"pmid":"1372523","id":"PMC_1372523","title":"Functional expression and growth factor activation of an epitope-tagged p44 mitogen-activated protein kinase, p44mapk.","date":"1992","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/1372523","citation_count":159,"is_preprint":false},{"pmid":"12374781","id":"PMC_12374781","title":"Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism.","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12374781","citation_count":145,"is_preprint":false},{"pmid":"7579336","id":"PMC_7579336","title":"Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7579336","citation_count":142,"is_preprint":false},{"pmid":"29454854","id":"PMC_29454854","title":"ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29454854","citation_count":138,"is_preprint":false},{"pmid":"15531431","id":"PMC_15531431","title":"Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways.","date":"2004","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/15531431","citation_count":137,"is_preprint":false},{"pmid":"36281999","id":"PMC_36281999","title":"ERK1/2 in immune signalling.","date":"2022","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/36281999","citation_count":134,"is_preprint":false},{"pmid":"17928626","id":"PMC_17928626","title":"17beta-estradiol induces the translocation of the estrogen receptors ESR1 and ESR2 to the cell membrane, MAPK3/1 phosphorylation and proliferation of cultured immature rat Sertoli cells.","date":"2007","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/17928626","citation_count":128,"is_preprint":false},{"pmid":"7803762","id":"PMC_7803762","title":"The mitogen-activated protein kinases, ERK1 and ERK2.","date":"1994","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/7803762","citation_count":127,"is_preprint":false},{"pmid":"20237411","id":"PMC_20237411","title":"ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20237411","citation_count":120,"is_preprint":false},{"pmid":"1717989","id":"PMC_1717989","title":"Mouse Erk-1 gene product is a serine/threonine protein kinase that has the potential to phosphorylate tyrosine.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1717989","citation_count":119,"is_preprint":false},{"pmid":"30535440","id":"PMC_30535440","title":"Mechanisms shaping the role of ERK1/2 in cellular senescence (Review).","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30535440","citation_count":109,"is_preprint":false},{"pmid":"22737980","id":"PMC_22737980","title":"PTEN regulation of ERK1/2 signaling in cancer.","date":"2012","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/22737980","citation_count":94,"is_preprint":false},{"pmid":"22562245","id":"PMC_22562245","title":"Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22562245","citation_count":93,"is_preprint":false},{"pmid":"19242111","id":"PMC_19242111","title":"Total ERK1/2 activity regulates cell proliferation.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19242111","citation_count":90,"is_preprint":false},{"pmid":"12070303","id":"PMC_12070303","title":"Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12070303","citation_count":90,"is_preprint":false},{"pmid":"8947482","id":"PMC_8947482","title":"Calcium-dependent activation of Erk-1 and Erk-2 after hypo-osmotic astrocyte swelling.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8947482","citation_count":89,"is_preprint":false},{"pmid":"18449171","id":"PMC_18449171","title":"Activation of Erk1/2 and Akt following unilateral ureteral obstruction.","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/18449171","citation_count":84,"is_preprint":false},{"pmid":"7775600","id":"PMC_7775600","title":"Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition.","date":"1995","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7775600","citation_count":83,"is_preprint":false},{"pmid":"26235619","id":"PMC_26235619","title":"Functional Redundancy of ERK1 and ERK2 MAP Kinases during Development.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26235619","citation_count":82,"is_preprint":false},{"pmid":"25060812","id":"PMC_25060812","title":"Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation.","date":"2014","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/25060812","citation_count":82,"is_preprint":false},{"pmid":"8640866","id":"PMC_8640866","title":"Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex.","date":"1996","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8640866","citation_count":78,"is_preprint":false},{"pmid":"7687743","id":"PMC_7687743","title":"Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7687743","citation_count":76,"is_preprint":false},{"pmid":"37892237","id":"PMC_37892237","title":"Navigating the ERK1/2 MAPK Cascade.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37892237","citation_count":75,"is_preprint":false},{"pmid":"28218391","id":"PMC_28218391","title":"MAPK3/1 participates in the activation of primordial follicles through mTORC1-KITL signaling.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28218391","citation_count":74,"is_preprint":false},{"pmid":"18161916","id":"PMC_18161916","title":"AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18161916","citation_count":73,"is_preprint":false},{"pmid":"31662208","id":"PMC_31662208","title":"Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies.","date":"2019","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31662208","citation_count":68,"is_preprint":false},{"pmid":"25401279","id":"PMC_25401279","title":"ERK1 and ERK2 regulate chondrocyte terminal differentiation during endochondral bone formation.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25401279","citation_count":62,"is_preprint":false},{"pmid":"25174327","id":"PMC_25174327","title":"Erk1/2 activation and modulation of STAT3 signaling in oral cancer.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25174327","citation_count":59,"is_preprint":false},{"pmid":"28438610","id":"PMC_28438610","title":"Hyperglycemia Increases Interstitial Cells of Cajal via MAPK1 and MAPK3 Signaling to ETV1 and KIT, Leading to Rapid Gastric Emptying.","date":"2017","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28438610","citation_count":59,"is_preprint":false},{"pmid":"15728253","id":"PMC_15728253","title":"Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15728253","citation_count":57,"is_preprint":false},{"pmid":"33686185","id":"PMC_33686185","title":"Cannabidiol induces autophagy via ERK1/2 activation in neural cells.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33686185","citation_count":57,"is_preprint":false},{"pmid":"16439799","id":"PMC_16439799","title":"AsialoGM1 and TLR5 cooperate in flagellin-induced nucleotide signaling to activate Erk1/2.","date":"2006","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16439799","citation_count":56,"is_preprint":false},{"pmid":"31196980","id":"PMC_31196980","title":"Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31196980","citation_count":56,"is_preprint":false},{"pmid":"19011018","id":"PMC_19011018","title":"CTGF is increased in basal deposits and regulates matrix production through the ERK (p42/p44mapk) MAPK and the p38 MAPK signaling pathways.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19011018","citation_count":50,"is_preprint":false},{"pmid":"9453550","id":"PMC_9453550","title":"Region-specific targets of p42/p44MAPK signaling in rat brain.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9453550","citation_count":50,"is_preprint":false},{"pmid":"20074457","id":"PMC_20074457","title":"Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice.","date":"2009","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20074457","citation_count":49,"is_preprint":false},{"pmid":"28302472","id":"PMC_28302472","title":"ERK1 and ERK2 activation modulates diet-induced obesity in mice.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28302472","citation_count":48,"is_preprint":false},{"pmid":"16888810","id":"PMC_16888810","title":"ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16888810","citation_count":48,"is_preprint":false},{"pmid":"28982763","id":"PMC_28982763","title":"Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28982763","citation_count":45,"is_preprint":false},{"pmid":"29494492","id":"PMC_29494492","title":"Importance of ERK1/2 in Regulation of Protein Translation during Oocyte Meiosis.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29494492","citation_count":44,"is_preprint":false},{"pmid":"18047785","id":"PMC_18047785","title":"RGS protein specificity towards Gq- and Gi/o-mediated ERK 1/2 and Akt activation, in vitro.","date":"2007","source":"Journal of biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18047785","citation_count":44,"is_preprint":false},{"pmid":"26202867","id":"PMC_26202867","title":"Isoniazid prevents Nrf2 translocation by inhibiting ERK1 phosphorylation and induces oxidative stress and apoptosis.","date":"2015","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/26202867","citation_count":44,"is_preprint":false},{"pmid":"20075392","id":"PMC_20075392","title":"The DSCs-expressed CD82 controls the invasiveness of trophoblast cells via integrinbeta1/MAPK/MAPK3/1 signaling pathway in human first-trimester pregnancy.","date":"2010","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/20075392","citation_count":43,"is_preprint":false},{"pmid":"23124701","id":"PMC_23124701","title":"The release of EGF domain from EGF-like factors by a specific cleavage enzyme activates the EGFR-MAPK3/1 pathway in both granulosa cells and cumulus cells during the ovulation process.","date":"2012","source":"The Journal of reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/23124701","citation_count":42,"is_preprint":false},{"pmid":"19622016","id":"PMC_19622016","title":"Thioredoxin regulates cell cycle via the ERK1/2-cyclin D1 pathway.","date":"2009","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19622016","citation_count":41,"is_preprint":false},{"pmid":"20716207","id":"PMC_20716207","title":"Anaplasma phagocytophilum AptA modulates Erk1/2 signalling.","date":"2010","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/20716207","citation_count":41,"is_preprint":false},{"pmid":"26336084","id":"PMC_26336084","title":"ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1.","date":"2015","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/26336084","citation_count":40,"is_preprint":false},{"pmid":"25359475","id":"PMC_25359475","title":"Linear B-cell epitope mapping of MAPK3 and MAPK4 from Leishmania braziliensis: implications for the serodiagnosis of human and canine leishmaniasis.","date":"2014","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/25359475","citation_count":40,"is_preprint":false},{"pmid":"11185956","id":"PMC_11185956","title":"Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in rat-2 cells.","date":"2000","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/11185956","citation_count":38,"is_preprint":false},{"pmid":"16809450","id":"PMC_16809450","title":"Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16809450","citation_count":37,"is_preprint":false},{"pmid":"29259132","id":"PMC_29259132","title":"Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29259132","citation_count":37,"is_preprint":false},{"pmid":"33923899","id":"PMC_33923899","title":"ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth.","date":"2021","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33923899","citation_count":36,"is_preprint":false},{"pmid":"16712482","id":"PMC_16712482","title":"Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors.","date":"2006","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/16712482","citation_count":34,"is_preprint":false},{"pmid":"29286066","id":"PMC_29286066","title":"Effects of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation and cell survival in glioma cells.","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29286066","citation_count":33,"is_preprint":false},{"pmid":"25803847","id":"PMC_25803847","title":"Effect of the transient pharmacological inhibition of Mapk3/1 pathway on ovulation in mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25803847","citation_count":31,"is_preprint":false},{"pmid":"28814571","id":"PMC_28814571","title":"MicroRNA-15b deteriorates hypoxia/reoxygenation-induced cardiomyocyte apoptosis by downregulating Bcl-2 and MAPK3.","date":"2017","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/28814571","citation_count":29,"is_preprint":false},{"pmid":"29128363","id":"PMC_29128363","title":"GBP3 promotes glioma cell proliferation via SQSTM1/p62-ERK1/2 axis.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29128363","citation_count":28,"is_preprint":false},{"pmid":"26516701","id":"PMC_26516701","title":"Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26516701","citation_count":28,"is_preprint":false},{"pmid":"35768803","id":"PMC_35768803","title":"The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis.","date":"2022","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/35768803","citation_count":27,"is_preprint":false},{"pmid":"29982533","id":"PMC_29982533","title":"Human peroxidasin 1 promotes angiogenesis through ERK1/2, Akt, and FAK pathways.","date":"2019","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/29982533","citation_count":27,"is_preprint":false},{"pmid":"33662979","id":"PMC_33662979","title":"Cryptotanshinone Attenuates Ischemia/Reperfusion-induced Apoptosis in Myocardium by Upregulating MAPK3.","date":"2021","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33662979","citation_count":27,"is_preprint":false},{"pmid":"26586479","id":"PMC_26586479","title":"SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26586479","citation_count":27,"is_preprint":false},{"pmid":"25817573","id":"PMC_25817573","title":"Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25817573","citation_count":26,"is_preprint":false},{"pmid":"19777442","id":"PMC_19777442","title":"ERK-1 MAP kinase prevents TNF-induced apoptosis through bad phosphorylation and inhibition of Bax translocation in HeLa Cells.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19777442","citation_count":26,"is_preprint":false},{"pmid":"38581859","id":"PMC_38581859","title":"ALOX15B controls macrophage cholesterol homeostasis via lipid peroxidation, ERK1/2 and SREBP2.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38581859","citation_count":25,"is_preprint":false},{"pmid":"25442017","id":"PMC_25442017","title":"Functional status of STAT3 and MAPK3/1 signaling pathways in granulosa cells during bovine follicular deviation.","date":"2014","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/25442017","citation_count":25,"is_preprint":false},{"pmid":"32346136","id":"PMC_32346136","title":"JNK1 and ERK1/2 modulate lymphocyte homeostasis via BIM and DRP1 upon AICD induction.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/32346136","citation_count":25,"is_preprint":false},{"pmid":"31574951","id":"PMC_31574951","title":"Biological Effects of Shikonin in Human Gingival Fibroblasts via ERK 1/2 Signaling Pathway.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31574951","citation_count":25,"is_preprint":false},{"pmid":"37090055","id":"PMC_37090055","title":"Flavonoids as Strong Inhibitors of MAPK3: A Computational Drug Discovery Approach.","date":"2023","source":"International journal of analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37090055","citation_count":24,"is_preprint":false},{"pmid":"32918333","id":"PMC_32918333","title":"PARK7 enhances antioxidative-stress processes of BMSCs via the ERK1/2 pathway.","date":"2020","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32918333","citation_count":24,"is_preprint":false},{"pmid":"34681809","id":"PMC_34681809","title":"The Role of MAPK3/1 and AKT in the Acquisition of High Meiotic and Developmental Competence of Porcine Oocytes Cultured In Vitro in FLI Medium.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34681809","citation_count":22,"is_preprint":false},{"pmid":"25803100","id":"PMC_25803100","title":"Both ERK1 and ERK2 are required for enterovirus 71 (EV71) efficient replication.","date":"2015","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/25803100","citation_count":22,"is_preprint":false},{"pmid":"16512856","id":"PMC_16512856","title":"PI3K and ERK 1-2 regulate early stages during head regeneration in hydra.","date":"2006","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16512856","citation_count":22,"is_preprint":false},{"pmid":"26163823","id":"PMC_26163823","title":"ERK1/2 can feedback-regulate cellular MEK1/2 levels.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26163823","citation_count":22,"is_preprint":false},{"pmid":"17384289","id":"PMC_17384289","title":"Amyloid precursor protein modulates ERK-1 and -2 signaling.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17384289","citation_count":21,"is_preprint":false},{"pmid":"32841221","id":"PMC_32841221","title":"Cardiomyocyte adhesion and hyperadhesion differentially require ERK1/2 and plakoglobin.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32841221","citation_count":20,"is_preprint":false},{"pmid":"31877781","id":"PMC_31877781","title":"Isoform-Specific Roles of ERK1 and ERK2 in Arteriogenesis.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31877781","citation_count":19,"is_preprint":false},{"pmid":"31013829","id":"PMC_31013829","title":"Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013829","citation_count":19,"is_preprint":false},{"pmid":"22303456","id":"PMC_22303456","title":"ERK1 regulates the hematopoietic stem cell niches.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22303456","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50354,"output_tokens":7865,"usd":0.134519,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17213,"output_tokens":7780,"usd":0.140283,"stage2_stop_reason":"end_turn"},"total_usd":0.274802,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"Bacterially expressed mouse Erk-1 is an active serine/threonine kinase that also autophosphorylates on tyrosine; treatment with serine/threonine phosphatase 2A or tyrosine phosphatase 1B significantly decreased its kinase activity, and Erk-1 could reactivate ribosomal protein S6 kinase (S6KII) in vitro.\",\n      \"method\": \"Bacterial expression, in vitro kinase assay, phosphatase treatment, substrate reactivation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with enzymatic assays and phosphatase treatment in a single focused study\",\n      \"pmids\": [\"1717989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"p44mapk (ERK1) is activated in a biphasic manner by growth factors (alpha-thrombin, PDGF, serum); activation requires dual phosphorylation on tyrosine and threonine, and the late/sustained phase of activation correlates strictly with mitogenic potential and DNA synthesis.\",\n      \"method\": \"Epitope-tagged expression in fibroblasts, in vitro kinase assay (myelin basic protein phosphorylation), phosphoamino acid analysis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstituted functional kinase assay replicated across multiple growth factor stimuli, independently corroborated by other papers in the corpus\",\n      \"pmids\": [\"1372523\", \"1603090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Activation of p42mapk/p44mapk is required for growth factor-stimulated fibroblast proliferation and gene transcription; antisense reduction of p42/p44mapk expression (by ~90%) or overexpression of kinase-deficient mutants (T192A or Y194F) inhibited MAP kinase activation, collagenase promoter-driven transcription, and cell growth in proportion to the extent of MAP kinase inhibition.\",\n      \"method\": \"Antisense RNA expression, dominant-negative kinase mutant overexpression, reporter gene assay (CAT), cell growth assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent loss-of-function approaches (antisense and dominant-negative), replicated phenotypes, multiple orthogonal readouts\",\n      \"pmids\": [\"8397401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Upon mitogenic stimulation, p42mapk and p44mapk translocate from the cytoplasm into the nucleus rapidly (within 15 min) and persistently (throughout G1); this translocation is reversible, coupled to mitogenic potential, and does not occur with non-mitogenic stimuli. In contrast, the upstream activator p45mapkk remains cytoplasmic even during prolonged stimulation.\",\n      \"method\": \"Immunofluorescence with specific antibodies, transfection of epitope-tagged recombinant MAP kinases, subcellular fractionation, live cell imaging\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization with multiple methods (antibodies + tagged constructs), functional correlation to mitogenic stimulus established, independently reproduced across labs\",\n      \"pmids\": [\"8394845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Human p44erk1 (ERK1) expressed as a GST fusion in E. coli autophosphorylates at the regulatory Tyr-204 (and additional sites); activity is strongly reduced by tyrosine phosphatase CD45 but not by serine/threonine phosphatase 2A; p56lck phosphorylates ERK1 at two autophosphorylation sites including Tyr-204; MAP kinase kinase (MEK) further activates ERK1 primarily through enhanced tyrosine phosphorylation.\",\n      \"method\": \"Bacterial expression (GST fusion), in vitro kinase assay (myelin basic protein substrate), phosphatase treatment, site-directed mutagenesis (K71A), MEK activation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in vitro with mutagenesis and multiple phosphatase/kinase experiments in a single rigorous study\",\n      \"pmids\": [\"7687743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The sustained (late) phase of p44mapk activation, but not the transient early phase, is specifically required for mitogenic signaling; pertussis toxin abolished the late phase and mitogenicity; non-mitogenic stimuli (thrombin-receptor peptide) induced only the early phase. Co-stimulation of FGF with TMP (a non-mitogenic agonist) synergistically potentiated late-phase p44mapk activation and DNA synthesis.\",\n      \"method\": \"In vitro kinase assay, pharmacological inhibition (pertussis toxin, hirudin), DNA synthesis assay (3H-thymidine incorporation)\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pharmacological perturbations and kinetics correlated with mitogenic readout, corroborated by other studies in the corpus\",\n      \"pmids\": [\"8380983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Ligation of beta1 integrins (by fibronectin adhesion or antibody cross-linking) rapidly activates p44erk-1 and p42erk-2 through tyrosine phosphorylation; disruption of actin filaments with cytochalasin D completely abolishes this integrin-mediated MAP kinase activation, indicating actin cytoskeleton integrity is required.\",\n      \"method\": \"Cell adhesion assay, anti-integrin antibody cross-linking, immunoprecipitation kinase assay, cytochalasin D treatment, phosphotyrosine Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional readouts with pharmacological perturbation, single lab, two orthogonal approaches\",\n      \"pmids\": [\"7814385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Sustained p42/p44MAPK (ERK1/2) activation during G1 phase is required to pass the restriction point; p44mapk and p42mapk activities are elevated throughout G1 and decline to negligible values at the G1/S transition, whereas CDK2 activity continues to rise through S phase.\",\n      \"method\": \"Cell cycle synchronization, immunoprecipitation kinase assay (MBP substrate), phosphoamino acid analysis, CDK2 activity assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — quantitative kinase assays across defined cell cycle stages with multiple synchronization methods, independently replicated across the corpus\",\n      \"pmids\": [\"7775600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Persistent activation of p42/p44MAPK positively regulates cyclin D1 expression: dominant-negative MKK1, kinase-dead p44MAPK, or MKP-1 overexpression strongly inhibited cyclin D1 promoter activity and protein; constitutively active MKK1 increased cyclin D1 in a growth factor-independent manner; activation of the Raf→MKK1→p42/p44MAPK cascade alone (via DeltaRaf-1:ER chimera) was sufficient to fully induce cyclin D1.\",\n      \"method\": \"Co-transfection of dominant-negative and constitutively active constructs, reporter gene assay (cyclin D1 promoter-luciferase/CAT), Western blot, inducible Raf-ER chimera\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple gain- and loss-of-function approaches with direct promoter readout and protein-level confirmation, independently corroborated\",\n      \"pmids\": [\"8702807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The p42/p44MAPK cascade induces expression of the dual-specificity phosphatases MKP-1 and MKP-2, forming a negative feedback loop; constitutively active MKK-1 or v-ras caused constitutive MKP-1/MKP-2 expression, and the MEK inhibitor PD098059 blocked both MAP kinase activation and MKP induction.\",\n      \"method\": \"Western blot with specific antibodies, dominant active/oncogenic constructs, pharmacological inhibition (PD098059), inducible DeltaRaf-1:ER chimera\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple gain-of-function models and pharmacological inhibition converge on the same conclusion, independently replicated\",\n      \"pmids\": [\"8995446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p42MAPK and p44MAPK directly phosphorylate MKP-1 on two C-terminal serine residues (Ser359 and Ser364) both in vivo and in vitro; this phosphorylation does not alter MKP-1's intrinsic phosphatase activity toward p44MAPK but stabilizes MKP-1 protein by attenuating ubiquitin-proteasome-mediated degradation.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (Ser359/Ser364), ubiquitin-proteasome inhibitor experiments, pulse-chase protein stability assay, in vivo phosphorylation\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis plus in vivo confirmation, published in Science, multiple orthogonal methods in one study\",\n      \"pmids\": [\"10617468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ERK1/2 directly phosphorylates sphingosine kinase 1 (SphK1) at Ser225, activating its enzyme activity and inducing translocation from the cytosol to the plasma membrane; mutation of Ser225 abolishes agonist-mediated SphK1 activation and membrane translocation.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (Ser225), subcellular fractionation, enzyme activity assay, multiple lines of evidence for ERK1/2 as the kinase\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro phosphorylation, mutagenesis, and membrane localization assay with multiple orthogonal methods in one study\",\n      \"pmids\": [\"14532121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK1 and ERK2 are both required for T cell positive selection in vivo; ERK1/2 activity is selectively retained during beta-selection-driven proliferation but is not required for completion of differentiation to the CD4+CD8+ preselection stage; ERK1/2 differentially affects CD4 vs. CD8 T cell maturation.\",\n      \"method\": \"Targeted gene deletion (Erk1 and Erk2 knockout mice), flow cytometry, thymocyte developmental analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic loss-of-function with defined cellular phenotypes, single and double knockout analysis\",\n      \"pmids\": [\"16226508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERK1/2 in granulosa cells are essential in vivo for LH-induced oocyte resumption of meiosis, ovulation, and luteinization; C/EBPbeta is a critical downstream transcriptional mediator of ERK1/2 activation in this pathway, as demonstrated by granulosa cell-specific disruption of Cebpb.\",\n      \"method\": \"Conditional knockout of Erk1 and Erk2 in mouse granulosa cells, genetic epistasis (Cebpb knockout), biochemical analyses, in vivo ovulation assay\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockouts in vivo with pathway epistasis, published in Science, multiple orthogonal readouts\",\n      \"pmids\": [\"19443782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Total ERK1/2 activity level (not isoform identity) is the key determinant for cell proliferation; combined single and double ERK1/ERK2 silencing showed that the apparent dominant role of ERK2 was due to its higher expression level, not isoform-specific function; ERK1 contribution is revealed when ERK2 activation is experimentally clamped.\",\n      \"method\": \"siRNA silencing of ERK1 and/or ERK2, cell proliferation assay, expression level analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with quantitative proliferation readout, single lab, single primary method\",\n      \"pmids\": [\"19242111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ERK1/2 and Akt1 (but not Akt2) crosstalk regulates arterial morphogenesis; suppression of PI3K/Akt1 activity restores ERK1/2 activation and rescues arterial development defects in synectin-deficient mice and zebrafish; constitutively active ERK1/2 constructs in endothelial cells are sufficient to restore impaired arteriogenesis.\",\n      \"method\": \"Genetic knockouts (synectin-deficient mice), Akt1/Akt2-specific knockdowns, constitutively active ERK1/2 construct, in vivo and in vitro arterial morphogenesis assays, zebrafish knockdown\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (mouse and zebrafish), rescue experiments with constitutively active construct, multiple orthogonal approaches\",\n      \"pmids\": [\"20237411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK1 and ERK2 are functionally redundant during mouse development; total ERK1/2 activity level determines developmental outcome (placenta and embryo viability); transgenic expression of ERK1 fully rescues the embryonic and placental lethal phenotype caused by loss of ERK2.\",\n      \"method\": \"Genetic complementation in mice (multiple Erk1/Erk2 allele combinations), transgenic ERK1 rescue, developmental outcome scoring\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo allelic series and full genetic rescue establish functional redundancy conclusively\",\n      \"pmids\": [\"26235619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK1 and ERK2 regulate chondrocyte terminal differentiation; conditional knockout of ERK1/2 in hypertrophic chondrocytes (Osx-Cre) caused expanded hypertrophic zones, decreased Mmp13 and Osteopontin, and downregulation of Egr1/Egr2 transcription factors; MEK1-ERK signaling activates the Osteopontin promoter in part through Egr1 and Egr2.\",\n      \"method\": \"Conditional knockout (Osx-Cre), histology, in situ hybridization, qRT-PCR, transient transfection reporter assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional knockout with defined molecular mechanism and reporter assay validation\",\n      \"pmids\": [\"25401279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK1 regulates hematopoietic stem cell niches by controlling osteoclastogenesis through M-CSF receptor (M-CSFR) expression on myeloid progenitors; ERK1-deficient mice show mild osteopetrosis, impaired HSC lodging and homing, reduced GMP frequency, and decreased M-CSFR expression on hematopoietic progenitors upstream of osteoclasts.\",\n      \"method\": \"ERK1 knockout mice, serial bone marrow transplantation, flow cytometry, in vitro and in vivo osteoclastogenesis assay, Western blot (M-CSFR expression)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic knockout with defined cellular phenotype and molecular mechanism, single lab\",\n      \"pmids\": [\"22303456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERK1/2 phosphorylates INTS11, the catalytic subunit of the Integrator complex, following EGF stimulation; activated ERK1/2 is recruited to immediate early genes at their promoters; Integrator is required to transduce ERK1/2 transcriptional responses at immediate early genes and their enhancers.\",\n      \"method\": \"Pharmacological ERK inhibition, ChIP-seq, Integrator subunit depletion, phosphorylation assays, cancer cell growth assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and phosphorylation data with depletion experiments, single lab\",\n      \"pmids\": [\"28982763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDAC6 deacetylates ERK1 at Lys-72 to stimulate its activity; CBP and p300 acetyltransferases acetylate ERK1; acetylation-mimicking mutation K72Q reduces ERK1 phosphorylation and enzymatic activity in vitro toward ELK1; ERK1 and HDAC6 form a positive feed-forward loop (ERK1 phosphorylates HDAC6 to increase its deacetylase activity, and HDAC6 deacetylates ERK1 to increase its kinase activity).\",\n      \"method\": \"Co-IP, HDAC6 knockdown, HDAC inhibitor treatment, site-directed mutagenesis (K72Q, K72R), in vitro kinase assay (ELK1 substrate), mass spectrometry (acetylation site identification), luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, mass spectrometry identification of acetylation site, multiple orthogonal methods in one study\",\n      \"pmids\": [\"29259132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SUV420H1 trimethylates ERK1 at Lys-302 and Lys-361; substitution of these methylation sites diminishes ERK1 phosphorylation; SUV420H1 knockdown reduces phospho-ERK1, total ERK1 protein, and ERK1 transcript levels.\",\n      \"method\": \"In vitro methylation assay, site-directed mutagenesis (K302/K361), SUV420H1 knockdown, Western blot, qRT-PCR\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro methylation assay with mutagenesis and knockdown, single lab\",\n      \"pmids\": [\"26586479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK1/2 can feedback-regulate MEK1/2 levels: ERK1/2 activity upregulates MEK1 at the transcriptional level and downregulates MEK2 at the post-translational level via the proteasome; ERK1/2 knockdown abrogates both regulations.\",\n      \"method\": \"ΔRaf-1:ER and B-Raf(V600E) inducible systems, ERK1/2 siRNA knockdown, qPCR, luciferase promoter and 3'UTR reporters, proteasome inhibitors (MG132, bortezomib), Western blot\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods and genetic rescue, single lab\",\n      \"pmids\": [\"26163823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Transient pharmacological inhibition of MAPK3/1 (with PD0325901) abolishes LH/hCG-induced ovulation in mice; MAPK3/1 regulates ovulation at least in part through transcriptional induction of Egr1, which binds to and activates the Ptgs2 (COX-2) promoter in granulosa cells.\",\n      \"method\": \"In vivo pharmacological inhibition, ChIP assay (Egr1 binding to Ptgs2 promoter), Egr1 siRNA knockdown in primary granulosa cells, qRT-PCR, ovulation counting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological inhibition plus ChIP epistasis and siRNA validation, multiple orthogonal methods\",\n      \"pmids\": [\"25803847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MAPK3/1 participates in primordial follicle activation through mTORC1-KITL signaling in pre-granulosa cells; inhibition of MAPK3/1 with U0126 reduces follicle activation and decreases phosphorylation of Tsc2, S6K1, and rpS6 (mTORC1 targets) and KITL expression, and also decreases Akt phosphorylation and Foxo3 nuclear export in oocytes.\",\n      \"method\": \"Ex vivo ovary culture, pharmacological inhibition (U0126), Western blot, immunofluorescence\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition with pathway-level readouts, single lab, multiple downstream markers measured\",\n      \"pmids\": [\"28218391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK1/2 loss in quiescent adult endothelium (endothelial Erk2 knockout on Erk1-null background) causes hypertension, decreased eNOS expression, increased endothelin-1, widespread endothelial-to-mesenchymal transition (EndMT) via TGFβ signaling, fibrosis, and death; ERK1/2 signaling is required to suppress TGFβ pathway and maintain endothelial identity.\",\n      \"method\": \"Conditional knockout (endothelial-specific Erk2 deletion on Erk1-/- background), endothelial fate mapping, immunostaining, RNA-seq, HUVEC in vitro knockdown, computational causal modeling\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional knockout with in vitro mechanistic validation, fate mapping, transcriptomic causal analysis, and multiple endpoints\",\n      \"pmids\": [\"31196980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Erk1/2 directly phosphorylate FGF receptor 1 (FGFR1) at a specific serine residue and multiple threonine residues in FRS2, substantially reducing tyrosine phosphorylation of FGFR1 and its downstream signaling; simultaneous inhibition of both Erk1/2 and p38 kinase leads to prolonged FGFR1/FRS2 tyrosine phosphorylation, revealing a crosstalk between p38 and Erk1/2 in negative feedback of FGF signaling.\",\n      \"method\": \"Pharmacological inhibition (ERK and p38 inhibitors), phospho-Western blot, anisomycin p38 activation, stable cell lines (FGFR1-expressing NIH3T3 and U2OS)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with phospho-readouts at multiple nodes, single lab, two orthogonal cell systems\",\n      \"pmids\": [\"31013829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"S-nitrosylation of ERK1 at Cys183 inhibits ERK1/2 phosphorylation and promotes glioma cell apoptosis; C183A mutation (preventing S-nitrosylation) partially reverses NO donor-induced reductions in cell viability and ERK1/2 phosphorylation; inverse correlation between S-nitrosylation and phosphorylation was confirmed in human glioma tissues.\",\n      \"method\": \"Biotin switch assay, site-directed mutagenesis (C183A), Western blot, flow cytometry (apoptosis), cell viability assay, NO donor treatment\",\n      \"journal\": \"International journal of molecular medicines\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus biotin switch and cellular functional assay, single lab\",\n      \"pmids\": [\"29286066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Region-specific subcellular localization of activated p42/p44MAPK determines their functional targets in vivo: in hippocampal neurons after ECS, activated MAPKs are cytoplasmic and phosphorylate cytoplasmic substrate MAP2c but not nuclear c-Fos; in cortical neurons, activated MAPKs localize to both nucleus and cytoplasm and phosphorylate both MAP2c and c-Fos.\",\n      \"method\": \"In vivo electroconvulsive shock, immunohistochemistry (phospho-MAPK), pharmacological inhibition (PD098059), immunoblot for MAP2c phosphorylation, c-Fos immunohistochemistry\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo localization linked to substrate phosphorylation via pharmacological inhibition, single lab\",\n      \"pmids\": [\"9453550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERK-1 kinase activity prevents TNF+cycloheximide-induced apoptosis through phosphorylation of Bad and inhibition of Bax translocation to mitochondria, thereby preventing cytochrome c release; a kinase-dead ERK-1 (K71R) sensitizes cells to apoptosis; these effects are mediated through the intrinsic mitochondrial pathway.\",\n      \"method\": \"ERK-1 and K71R kinase-dead overexpression in HeLa cells, Western blot (Bad phosphorylation, Bax, Bcl-2, cytochrome c), cell death assay, caspase inhibitor experiments\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and kinase-dead constructs with mechanistic downstream readouts, single lab\",\n      \"pmids\": [\"19777442\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAPK3 (ERK1) is a proline-directed serine/threonine kinase activated by MEK1/2-mediated dual phosphorylation at Thr202 and Tyr204; it translocates from the cytoplasm to the nucleus upon mitogenic stimulation (coupled to its sustained activation), where it phosphorylates transcription factors (Elk1, c-Fos, Egr1) and cytoplasmic substrates (MAP2c, FRS2, FGFR1, Bad, SphK1 Ser225), and is regulated post-translationally by acetylation (CBP/p300, reversed by HDAC6 at Lys-72), methylation (SUV420H1 at Lys-302/361), and S-nitrosylation (at Cys183); it operates redundantly with ERK2 in most developmental and proliferative contexts (total ERK activity being the key determinant), while exhibiting isoform-specific roles in macrophage/osteoclast biology and arteriogenesis; and it participates in multiple negative feedback loops by phosphorylating and stabilizing MKP-1/MKP-2 phosphatases and by transcriptionally and post-translationally regulating MEK1/2 levels.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MAPK3 (ERK1) is a dual-specificity-regulated proline-directed serine/threonine kinase that serves as a terminal effector of the Raf\\u2192MEK\\u2192ERK mitogenic cascade, converting growth factor and integrin signals into proliferative and developmental gene-expression programs [#0, #1, #6, #8]. Its catalytic activation requires dual phosphorylation on tyrosine and threonine by MAP kinase kinase (MEK), and it can autophosphorylate on tyrosine; activity is reversed by serine/threonine and tyrosine phosphatases [#0, #4]. A defining feature is that the sustained, late phase of activation\\u2014not the transient early phase\\u2014is coupled to nuclear translocation throughout G1 and is specifically required for passage through the restriction point, induction of cyclin D1, and DNA synthesis [#3, #5, #7, #8]. In the nucleus and cytoplasm ERK1 phosphorylates a defined set of substrates including the transcriptional machinery via ELK1 and immediate-early gene programs (Egr1, c-Fos, the Integrator subunit INTS11), the cytoskeletal protein MAP2c, the pro-apoptotic regulator Bad, sphingosine kinase 1 (Ser225), and components of receptor feedback (FGFR1/FRS2) [#11, #17, #19, #20, #28, #29]. ERK1 embeds itself in multiple negative-feedback loops\\u2014directly phosphorylating and stabilizing the dual-specificity phosphatases MKP-1/MKP-2, attenuating FGFR1/FRS2 signaling, and transcriptionally and post-translationally tuning MEK1/2 levels [#9, #10, #22, #26]. Its kinase output is further set by reversible post-translational modification: acetylation by CBP/p300 reversed by HDAC6 deacetylation at Lys-72, SUV420H1-mediated methylation at Lys-302/361, and inhibitory S-nitrosylation at Cys183 [#20, #21, #27]. In vivo, ERK1 functions largely redundantly with ERK2, with total ERK activity rather than isoform identity being the determinant of proliferation and development, while ERK1-selective roles emerge in osteoclast/HSC-niche and arteriogenic contexts [#14, #16, #18]; genetic studies establish requirements in T-cell positive selection, ovarian follicle activation, ovulation and luteinization, chondrocyte terminal differentiation, and maintenance of endothelial identity against TGF\\u03b2-driven EndMT [#12, #13, #15, #17, #23, #24, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established ERK1 as a bona fide serine/threonine kinase whose activity depends on phosphorylation state and which can relay signal to downstream kinases, defining it as an enzyme in a cascade.\",\n      \"evidence\": \"Bacterial expression of mouse Erk-1 with in vitro kinase, phosphatase treatment, and S6KII reactivation assays\",\n      \"pmids\": [\"1717989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological upstream activator not yet identified\", \"In vitro autophosphorylation may not reflect cellular activation mechanism\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed that ERK1 activation by growth factors is biphasic and that the sustained late phase, not transient activation, correlates with mitogenic outcome\\u2014linking activation kinetics to cell fate.\",\n      \"evidence\": \"Epitope-tagged ERK1 in fibroblasts, in vitro MBP kinase assays, phosphoamino acid analysis across multiple growth factors\",\n      \"pmids\": [\"1372523\", \"1603090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for sustained vs transient kinetics unresolved\", \"Nuclear vs cytoplasmic activity not yet separated\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrated ERK1/2 are causally required for growth-factor-driven proliferation and gene transcription, moving beyond correlation to functional necessity.\",\n      \"evidence\": \"Antisense knockdown and dominant-negative (T192A/Y194F) mutants with reporter and growth assays in fibroblasts\",\n      \"pmids\": [\"8397401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets not defined here\", \"ERK1 vs ERK2 contributions not separated\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined the regulated nuclear translocation of ERK1/2 as mitogen-specific and persistent through G1, while the upstream activator stays cytoplasmic\\u2014establishing spatial control of signaling output.\",\n      \"evidence\": \"Immunofluorescence, tagged-construct transfection, and subcellular fractionation in stimulated cells\",\n      \"pmids\": [\"8394845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Translocation machinery/NLS-like determinants not identified\", \"Nuclear substrates not yet enumerated\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Resolved the activation mechanism biochemically\\u2014autophosphorylation at Tyr-204, differential phosphatase sensitivity, and MEK acting mainly via tyrosine phosphorylation.\",\n      \"evidence\": \"GST-ERK1 in vitro kinase assays, CD45/PP2A treatment, K71A mutagenesis, and MEK activation\",\n      \"pmids\": [\"7687743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of autophosphorylation vs MEK unclear\", \"p56lck phosphorylation physiological relevance untested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Connected ERK1 activation to upstream adhesion and cytoskeletal context, showing integrin ligation activates ERK1 in an actin-dependent manner.\",\n      \"evidence\": \"Integrin cross-linking/fibronectin adhesion with IP kinase assays and cytochalasin D disruption\",\n      \"pmids\": [\"7814385\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking actin to ERK activation undefined\", \"Single-lab pharmacological perturbation\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Tied sustained ERK1/2 activity to the cell-cycle restriction point, defining its temporal window of action during G1.\",\n      \"evidence\": \"Cell-cycle synchronization with IP kinase and CDK2 assays\",\n      \"pmids\": [\"7775600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct G1 effector substrates not identified in this study\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified cyclin D1 as a key transcriptional output coupling sustained ERK activity to G1 progression, providing a mechanistic effector for the restriction-point requirement.\",\n      \"evidence\": \"Dominant-negative/constitutively active MKK1 and kinase-dead ERK, MKP-1, and Raf-ER chimera with cyclin D1 promoter reporters\",\n      \"pmids\": [\"8702807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcription factors at the cyclin D1 promoter not pinpointed here\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Revealed that the ERK cascade induces its own negative regulators (MKP-1/MKP-2), establishing transcriptional feedback control of pathway duration.\",\n      \"evidence\": \"Constitutively active MKK1/v-ras, PD098059 inhibition, and Raf-ER chimera with phosphatase immunoblots\",\n      \"pmids\": [\"8995446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors mediating MKP induction not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed ERK1/2 directly phosphorylates and stabilizes MKP-1, adding a post-translational layer to feedback that shapes signal duration without altering phosphatase activity.\",\n      \"evidence\": \"In vitro kinase assay, Ser359/Ser364 mutagenesis, pulse-chase stability, and proteasome inhibition\",\n      \"pmids\": [\"10617468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The ubiquitin ligase targeting MKP-1 not identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that the subcellular location of activated ERK in vivo dictates which substrate class (cytoplasmic MAP2c vs nuclear c-Fos) is phosphorylated, linking localization to functional specificity in neurons.\",\n      \"evidence\": \"In vivo electroconvulsive shock with phospho-MAPK immunohistochemistry and PD098059 inhibition across neuron types\",\n      \"pmids\": [\"9453550\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of region-specific localization unknown\", \"Single-lab correlative localization\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Added SphK1 as a direct ERK1/2 substrate, coupling ERK activity to sphingolipid signaling and membrane translocation of an effector enzyme.\",\n      \"evidence\": \"In vitro kinase assay, Ser225 mutagenesis, subcellular fractionation, and enzyme activity assays\",\n      \"pmids\": [\"14532121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts of SphK1 activation by ERK1 not delineated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established an in vivo developmental requirement for ERK1/2 in T-cell positive selection, distinguishing proliferation-linked from differentiation-linked activity.\",\n      \"evidence\": \"Erk1 and Erk2 knockout mice with flow cytometric thymocyte analysis\",\n      \"pmids\": [\"16226508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate basis for selection vs differentiation distinction unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined an ovarian ERK1/2 program where C/EBP\\u03b2 is the critical transcriptional mediator for LH-induced ovulation and luteinization, mapping a tissue-specific effector.\",\n      \"evidence\": \"Granulosa-cell conditional Erk1/Erk2 and Cebpb knockouts with in vivo ovulation assays\",\n      \"pmids\": [\"19443782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERK1/2 substrates upstream of C/EBP\\u03b2 not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed ERK1 kinase activity is anti-apoptotic via Bad phosphorylation and suppression of Bax/cytochrome c release, placing ERK1 on the intrinsic mitochondrial survival axis.\",\n      \"evidence\": \"ERK1 and kinase-dead K71R overexpression in HeLa with Bad/Bax/cytochrome c immunoblots and death assays\",\n      \"pmids\": [\"19777442\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect Bad phosphorylation by ERK1 not fully resolved\", \"Single-lab overexpression system\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Tested whether ERK1 vs ERK2 functional differences reflect isoform identity, concluding total ERK activity (driven by expression level) governs proliferation.\",\n      \"evidence\": \"Single and combined ERK1/ERK2 siRNA silencing with proliferation and expression analysis\",\n      \"pmids\": [\"19242111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single primary method (siRNA)\", \"Contexts with genuine isoform-specific roles not excluded\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified an ERK1/2\\u2013Akt1 crosstalk node controlling arterial morphogenesis, with constitutively active ERK1/2 sufficient to rescue arteriogenesis defects.\",\n      \"evidence\": \"Synectin-deficient mice/zebrafish, Akt isoform knockdowns, and constitutively active ERK1/2 rescue in endothelium\",\n      \"pmids\": [\"20237411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial ERK substrates driving arteriogenesis unmapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established genetically that ERK1 and ERK2 are functionally redundant in development and that transgenic ERK1 rescues ERK2 loss\\u2014total activity, not isoform, sets developmental outcome.\",\n      \"evidence\": \"Mouse Erk1/Erk2 allelic series with transgenic ERK1 rescue and developmental scoring\",\n      \"pmids\": [\"26235619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue contexts with non-redundant roles not fully enumerated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped a chondrocyte terminal-differentiation program in which ERK1/2 acts through Egr1/Egr2 to control Osteopontin and Mmp13 expression.\",\n      \"evidence\": \"Osx-Cre conditional Erk1/2 knockout with histology, in situ hybridization, and Osteopontin promoter reporters\",\n      \"pmids\": [\"25401279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERK phosphorylation events upstream of Egr1/Egr2 not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed an ERK1-selective role in regulating the HSC niche via M-CSFR-dependent osteoclastogenesis, indicating isoform-specific functions in myeloid/bone biology.\",\n      \"evidence\": \"ERK1 knockout mice, bone-marrow transplantation, flow cytometry, and osteoclastogenesis assays\",\n      \"pmids\": [\"22303456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ERK1 to M-CSFR expression undefined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Added a methylation layer of ERK1 regulation, showing SUV420H1 trimethylates Lys-302/361 to sustain ERK1 phosphorylation and expression.\",\n      \"evidence\": \"In vitro methylation, K302/K361 mutagenesis, and SUV420H1 knockdown with immunoblot/qRT-PCR\",\n      \"pmids\": [\"26586479\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which methylation affects phosphorylation/transcript unclear\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated ERK1/2 feedback regulation of upstream MEK by oppositely controlling MEK1 (transcriptionally up) and MEK2 (proteasomally down), refining cascade homeostasis.\",\n      \"evidence\": \"\\u0394Raf-1:ER/B-Raf(V600E) systems, ERK siRNA, promoter/3'UTR reporters, and proteasome inhibitors\",\n      \"pmids\": [\"26163823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating MEK2 turnover not identified\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped the ovulation mechanism to ERK-driven Egr1 induction that activates the Ptgs2/COX-2 promoter, defining a direct transcriptional axis for fertility.\",\n      \"evidence\": \"In vivo PD0325901 inhibition, Egr1 ChIP at Ptgs2 promoter, and Egr1 siRNA in granulosa cells\",\n      \"pmids\": [\"25803847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERK substrate upstream of Egr1 not pinpointed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected ERK1/2 to primordial follicle activation via mTORC1-KITL signaling in pre-granulosa cells, broadening the ovarian role to earlier follicle stages.\",\n      \"evidence\": \"Ex vivo ovary culture with U0126 and immunoblot/immunofluorescence of mTORC1/Akt/Foxo3 markers\",\n      \"pmids\": [\"28218391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERK targets in the mTORC1-KITL axis unknown\", \"Pharmacological inhibition only\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the Integrator catalytic subunit INTS11 as an ERK1/2 substrate and showed Integrator transduces ERK transcriptional responses at immediate-early genes and enhancers.\",\n      \"evidence\": \"ERK inhibition, ChIP-seq, Integrator depletion, and phosphorylation assays in cancer cells\",\n      \"pmids\": [\"28982763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct INTS11 phosphosites and their consequences not fully defined\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Added inhibitory S-nitrosylation at Cys183 as a regulatory modification that suppresses ERK phosphorylation and promotes glioma apoptosis, linking NO signaling to ERK output.\",\n      \"evidence\": \"Biotin switch assay, C183A mutagenesis, apoptosis/viability assays, and human glioma tissue correlation\",\n      \"pmids\": [\"29286066\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Cys183 modification blocks activation loop phosphorylation unclear\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established acetylation/deacetylation control of ERK1 via CBP/p300 and HDAC6 at Lys-72, forming an ERK1\\u2013HDAC6 feed-forward loop that tunes kinase activity.\",\n      \"evidence\": \"Co-IP, HDAC6 knockdown, K72Q/K72R mutagenesis, in vitro ELK1 kinase assay, and mass spectrometry\",\n      \"pmids\": [\"29259132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological role of Lys-72 acetylation not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed ERK1/2 is required in quiescent endothelium to suppress TGF\\u03b2-driven EndMT and maintain endothelial identity, extending ERK function beyond proliferation to tissue homeostasis.\",\n      \"evidence\": \"Endothelial conditional Erk2 knockout on Erk1-null background with fate mapping, RNA-seq, and HUVEC knockdown\",\n      \"pmids\": [\"31196980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERK substrates suppressing the TGF\\u03b2 program not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated ERK1/2 directly phosphorylates FGFR1 and FRS2 to dampen receptor tyrosine phosphorylation, defining a negative-feedback brake on FGF signaling with p38 crosstalk.\",\n      \"evidence\": \"Pharmacological ERK/p38 inhibition with phospho-Western blots in FGFR1-expressing cell lines\",\n      \"pmids\": [\"31013829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific FRS2/FGFR1 phosphosites and their direct effects partially defined\", \"Single-lab pharmacology\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple post-translational modifications (acetylation, methylation, S-nitrosylation) integrate with MEK-driven activation-loop phosphorylation to set ERK1 output in vivo, and what distinguishes ERK1-selective contexts from redundant ones at the substrate level, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM cross-regulation to physiological signaling\", \"Substrate-level basis for ERK1-specific roles undefined\", \"Determinants of localization-dependent substrate selection unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 10, 11, 19, 20, 26, 29]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 4, 10, 11]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 17, 19, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 28]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 19, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 8, 9, 22, 26]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 13, 16, 17, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [17, 19, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [27, 29]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [13, 23, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAP2K1\", \"MKP-1/DUSP1\", \"HDAC6\", \"SUV420H1\", \"INTS11\", \"SphK1\", \"FGFR1\", \"FRS2\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}